Related Experiment Video

Updated: Mar 29, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

Pulmonary Exacerbations in Children with Cystic Fibrosis

Valerie Waters¹, Felix Ratjen²

¹1 Division of Infectious Diseases, and.

Annals of the American Thoracic Society

|November 24, 2015

Insights

Milder pulmonary exacerbations in cystic fibrosis (CF) children, often treated with oral antibiotics, have unclear impacts. Further research is needed to understand their effects on lung function and long-term health outcomes.

Area of Science:

Pediatric Pulmonology
Infectious Diseases
Genetics

Background:

Pulmonary exacerbations significantly impact cystic fibrosis (CF) patient outcomes.
Milder exacerbations in children, treated with oral antibiotics, have less defined clinical consequences.
Viral infections are common triggers for exacerbations in children with CF, leading to greater morbidity compared to healthy peers.

Purpose of the Study:

To investigate the impact of milder pulmonary exacerbations in children with CF.
To understand the clinical outcomes associated with milder exacerbations treated with oral antibiotics.
To clarify the long-term effects of these events on lung function and mortality.

Main Methods:

Analysis of recent clinical trials in pediatric CF populations.
Utilized symptom-based definitions for pulmonary exacerbations.
Compared symptom spectrum and treatment criteria fulfillment between children and older CF patients.

Main Results:

Symptom-based definitions revealed differences in exacerbation presentation between children and adults.
A significant number of children received treatment for events not meeting strict pulmonary exacerbation criteria.
Greater virus-related morbidity observed in CF children due to increased viral load, inflammation, and impaired mucociliary clearance.

Conclusions:

The clinical impact of milder pulmonary exacerbations in pediatric CF requires further investigation.
Additional research is necessary to determine the effects on lung function recovery, time to next exacerbation, and overall survival.
Refining exacerbation definitions and understanding treatment responses in children are crucial for improving CF care.

Read full analysis

Abstract:

Pulmonary exacerbations treated with intravenous antibiotics have significant, well-characterized negative consequences on clinical outcomes in cystic fibrosis (CF). The impact of milder exacerbations in children with CF, commonly treated with oral antibiotics, are less well defined. Pulmonary exacerbations have multiple triggers, but viral infections are particularly common in children. Children with CF and healthy control subjects have similar frequencies of viral respiratory infections, but there is evidence of greater virus-related morbidity in patients with CF, likely due to a combination of increased viral load, more pronounced inflammatory response, and more pronounced impairment in mucociliary clearance. In recent clinical trials in children, definitions have been used that are more symptom based rather than intervention based. These studies have demonstrated differences in the spectrum of symptoms between children and older patients but have also shown that, despite low threshold definitions, a considerable number of patients receive treatment for events not fulfilling the pulmonary exacerbation criteria. Additional research is needed to determine the impact of these milder exacerbations on lung function recovery and time to subsequent exacerbation as well as long-term outcomes such as mortality.

Keywords:

children cystic fibrosis pulmonary exacerbations virus

More Related Videos

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Pulmonary Cycle: Exhalation

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Articles linked to this work by shared authors, journal, and citation graph.

PangyPlot: multi-scale interactive visualization of pangenome variation graphs.

Bioinformatics (Oxford, England)·2026

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026

Post-infectious bronchiolitis obliterans in children: pathogenesis, treatment strategies, and future directions.

Current opinion in pediatrics·2026

Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Journal of magnetic resonance imaging : JMRI·2026

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.

Respiratory medicine·2026

The Impact of Nutritional Status on Lung Function Trajectories in Pediatric Patients With Primary Ciliary Dyskinesia.

Pediatric pulmonology·2026

See all related articles